Scholarlink

<p>The aim of this review is to summarize current knowledge on the diagnostic and therapeutic significance of antibodies against advanced glycation end-products (anti-AGEs). AGEs are formed through non-enzymatic reactions of reducing sugars with proteins, lipids, and nucleic acids, and their accumulation has been implicated in the pathogenesis of chronic diseases such as diabetes, atherosclerosis, cancer, and neurodegenerative disorders. This paper discusses anti-MGO modified proteins, anti-imidazolone, anti-pentosidine, anti-CML (including SIWA318H), anti-CEL, anti-CMA, and anti-GA-pyridine antibodies, with a focus on their potential applications in diagnostics (biomarkers, disease progression monitoring) and therapy (e.g., SIWA318H in pancreatic cancer). The review also highlights current limitations, particularly regarding clinical use in humans, and outlines perspectives for further research in this promising field.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic and therapeutic significance of selected antibodies against advanced glycation end-products (anti-AGEs)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月4日

查看全文
  • Julia Sobczyńska,
  • Jakub Federowicz,
  • Zuzanna Galińska,
  • Maciej Ziomek,
  • Wojciech Stach,
  • Agnieszka Bronowicka-Szydełko,
  • Katarzyna Madziarska

摘要

The aim of this review is to summarize current knowledge on the diagnostic and therapeutic significance of antibodies against advanced glycation end-products (anti-AGEs). AGEs are formed through non-enzymatic reactions of reducing sugars with proteins, lipids, and nucleic acids, and their accumulation has been implicated in the pathogenesis of chronic diseases such as diabetes, atherosclerosis, cancer, and neurodegenerative disorders. This paper discusses anti-MGO modified proteins, anti-imidazolone, anti-pentosidine, anti-CML (including SIWA318H), anti-CEL, anti-CMA, and anti-GA-pyridine antibodies, with a focus on their potential applications in diagnostics (biomarkers, disease progression monitoring) and therapy (e.g., SIWA318H in pancreatic cancer). The review also highlights current limitations, particularly regarding clinical use in humans, and outlines perspectives for further research in this promising field.